Krishna Institute of Medical Sciences Limited delivered robust top-line growth in the first quarter of FY27, with total revenue rising 36.1% year-on-year to ₹1,196 crore. The healthcare provider’s earnings call on August 4, 2026, highlighted strong operational momentum across its clusters, though net profit contracted significantly due to increased capital expenditures and interest burdens from recent expansion projects.

The company’s consolidated revenue from operations reached ₹1,180 crore, marking a 35.3% year-on-year increase and a 9.8% quarter-on-quarter rise. This growth was underpinned by substantial increases in both inpatient and outpatient volumes. Inpatient (IP) volumes climbed 26.6% year-on-year to 72,493, while outpatient (OP) volumes surged 28.5% to 6,58,617. These operational gains contributed to a 20.1% year-on-year growth in EBITDA, which stood at ₹240 crore, maintaining a margin of 20.1% compared to 20.27% in the previous year.

Despite the strong operational performance, profitability at the bottom line faced pressure. Net profit after tax (PAT) dropped 56.5% year-on-year to ₹37 crore, down from ₹85 crore in Q1FY26. This decline is attributed to higher depreciation charges and interest expenses associated with the company’s aggressive expansion strategy. Consolidated EPS for the quarter was reported at ₹104, reflecting a 2.3% quarter-on-quarter degrowth.

Financial Position and Debt Reduction

Management emphasized a strengthened balance sheet following significant capital raising initiatives. The company successfully completed a Qualified Institutional Placement (QIP), raising ₹1,500 crore, and executed a preferential allotment to promoters worth ₹600 crore. Proceeds from the QIP were primarily utilized to reduce debt, with ₹1,100 crore deployed to repay secured loans. As a result, total debt decreased from ₹3,250 crore as of March 31, 2026, to approximately ₹2,400 crore by early July 2026. Cash and cash equivalents stood at ₹505 crore as of June 30, 2026.

*Figures for Q1FY26 derived from disclosed growth percentages.

Expansion and Operational Updates

The company continued its geographic expansion, opening a new unit in Palakkad, Kerala, bringing its presence in the state to three hospitals. The Bengaluru cluster showed promising signs, with the Mahadevapura unit achieving EBITDA breakeven in less than seven months. Management expects the Electronic City unit to reach breakeven in the next one or two quarters. Additionally, the newly commissioned Kondapur facility in Telangana demonstrated strong initial traction, recording ₹45 crore in revenue during its first full month of operation in July 2026.

What the Numbers Show

The divergence between revenue growth and net profit contraction highlights the transitional phase KIMS Hospitals is undergoing. While core operations are generating strong cash flows and patient volumes are increasing, the heavy investment in greenfield projects like Kondapur and new units in Kerala and Bengaluru is temporarily suppressing bottom-line results. The strategic use of QIP proceeds to reduce debt suggests management is prioritizing balance sheet stability to fund future organic growth without excessive leverage. With mature clusters like Telangana and Andhra Pradesh continuing to deliver strong revenue and EBITDA growth, the company appears well-positioned to stabilize margins as new units ramp up over the next two to three years.

Krishna Institute of Medical Sciences has received in-principle approvals from both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Limited (NSE) for a preferential allotment of warrants to its promoter group. The company will issue 77,02,182 warrants, fully convertible into equity shares with a face value of ₹2 each, priced at not less than ₹779 per share. This capital raise strengthens the promoter stake through Dr. Abhinay Bollineni, Mr. Adwik Bollineni, and Bharas Ventures LLP, subject to final allotment and listing formalities.

The regulatory approvals were granted under Regulation 28(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company had submitted its application on June 17, 2026. Both exchanges have mandated strict compliance with internal controls to monitor trades executed by the proposed allottees before the allotment date. This is intended to prevent non-compliances regarding intra-day trading or sales in the company’s scrip prior to the security allotment, as required under Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

The company is advised to obtain undertakings from the allottees confirming they will not engage in intra-day trading or sell the scrip until the allotment date. The issuer bears sole responsibility for verifying these undertakings and ensuring compliance with Regulation 167(6) of the SEBI ICDR regulations. Any observed non-compliance post-verification may impact the listing of the shares.

Listing and Compliance Requirements

Following the allotment, Krishna Institute of Medical Sciences must file a listing application without delay, along with applicable fees, in terms of Regulation 14 of the LODR Regulations. As per Schedule XIX – Para (2) of the ICDR Regulations and SEBI circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/00094 dated June 21, 2023, the company must apply for listing within twenty days from the date of allotment. Failure to comply attracts fines as specified in the same circular.

The exchanges reserved the right to withdraw the in-principle approval if submitted information is found incomplete, incorrect, misleading, or false, or if it contravenes any rules, bye-laws, or regulations. The company must also secure all necessary statutory and other approvals from authorities including SEBI, RBI, and MCA before proceeding.

What the Numbers Show

The pricing of the warrants at not less than ₹779 per share establishes a clear valuation floor for this preferential issue. By structuring the issuance as fully convertible warrants rather than immediate equity, the promoters gain flexibility in timing the conversion while adhering to lock-in and trading restrictions imposed by the exchanges. The requirement for enhanced internal controls highlights the regulatory focus on preventing market abuse during the pre-allotment period.